Abstract / Description of output
Ovarian tissue cryopreservation (OTC) is increasingly offered globally as a fertility preservation strategy for both postpubertal women and prepubertal girls, with subsequent reimplantation of cryopreserved ovarian cortex resulting in a rapidly growing number of live births. There remains very limited evidence of efficacy from tissue stored when the patient was prepubertal or from conditions affecting the ovary directly, e.g., Turner syndrome. Although OTC is becoming a more established practice, several clinical dilemmas remain from a practical and ethical standpoint. This review discusses the challenges regarding optimal patient selection for the procedure, the use of OTC in patients with a poor prognosis, the potential of reimplantation of tissue contaminated with malignant cells, and the role of OTC in those with an intrinsic ovarian disorder.
Original language | English |
---|---|
Pages (from-to) | 559-564 |
Journal | Fertility and Sterility |
Volume | 122 |
Issue number | 4 |
Early online date | 31 May 2024 |
DOIs | |
Publication status | Published - Oct 2024 |
Keywords / Materials (for Non-textual outputs)
- Turner syndrome
- fertility preservation
- ovarian tissue cryopreservation
- ovarian transplantation